Glucocorticoid
Glucocorticoids are a class of steroid hormones and widely used anti-inflammatory and immunosuppressive agents that act primarily through the glucocorticoid receptor.
Glucocorticoids are a class of steroid hormones and widely used anti-inflammatory and immunosuppressive agents that act primarily through the glucocorticoid receptor. Endogenously, they are central regulators of metabolism, stress responses, and immune homeostasis; pharmacologically, they are among the most important therapies for inflammatory, autoimmune, allergic, and transplant-related conditions. Their effects are pleiotropic: they can suppress proinflammatory cytokine production, alter leukocyte trafficking and activation, and influence tissue repair and metabolic pathways.
In biomedical research, glucocorticoids are studied both as therapeutic agents and as biologically active signals within disease microenvironments. Recent work has highlighted their role in rheumatoid arthritis, Sjögren’s disease, inflammatory bowel and kidney disorders, cancer immunotherapy toxicity, and T-cell differentiation. At the same time, studies continue to examine glucocorticoid-related adverse effects, including infection risk, cardiovascular associations, and steroid resistance, as well as mechanisms of local glucocorticoid metabolism and receptor signaling.
Where the papers sit
10 papers from the last 6 months study glucocorticoid directly · updated from PubMed 9 Oct 2026
Study type 0 clinical trials · 7 observational · 2 human data · 1 unclassified
Themes 3 themes · 1 paradigm shift · 1 new direction
-
Autoimmune Inflammation and Treatment
Treatment optimization in giant cell arteritis centers on reducing glucocorticoid burden through methotrexate or tocilizumab, while other studies address Th17 homeostasis and B-cell receptor repertoire biomarkers. Serious infections and relapse remain key endpoints. The findings span giant cell arteritis, nephrotic syndrome and immune-cell biology. They do not support one coherent clinical direction.
4 papers · 40%
-
Inflammatory Disease Treatment
Glucocorticoid use is being weighed against relapse, infection and treatment burden across rheumatoid arthritis and ANCA-associated vasculitis. Belumosudil represents a nonsteroidal option in heavily pretreated chronic GVHD, while anticoagulation plus glucocorticoids is studied for NLRP3/NETosis in severe cerebral venous thrombosis. The diseases and endpoints differ too widely to show a shared direction.
4 papers · 40%
-
Systemic Lupus Burden
Early systemic lupus erythematosus is being framed as a cumulative disease burden, with flares and glucocorticoid exposure tracking multimorbidity. Cardiopulmonary and musculoskeletal complications recur alongside neuropsychiatric damage. Social support deficits appear to add longitudinal risk. The work points toward earlier risk stratification and steroid-sparing care, but does not establish a single intervention.
2 papers · 20%
Ongoing glucocorticoid exposure is not required for effective vasculitis maintenance and may be replaceable by steroid-sparing treatment
The ANCA-associated vasculitis maintenance cohort found no benefit from adding low-dose glucocorticoids for preventing major relapse, hospitalisation, or damage accumulation, while the giant cell arteritis comparison found glucocorticoid plus tocilizumab to be the only independently protective regimen and to reduce the composite burden relative to glucocorticoid monotherapy. Together, these findings replace the assumption that continued glucocorticoid treatment is necessary during vasculitis maintenance with a model in which steroid-sparing therapy can preserve control while reducing glucocorticoid exposure 42342286Jun 42365805Jun.
Glucocorticoid is an intrinsic homeostatic signal that maintains a non-inflammatory Th17 cell state
The Th17-cell model identified cell-intrinsic glucocorticoid production through CYP11A1 and sensing through the glucocorticoid receptor as a self-maintaining circuit that distinguishes homeostatic from pro-inflammatory Th17 cells. This assigns glucocorticoid a role beyond administered therapy, exposure, or treatment response: it is an endogenous regulator of immune-cell state and tissue homeostasis 42285103Jun.
Papers
The 10 papers from the last 6 months that study glucocorticoid directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Autoimmune Inflammation and Treatment (4)
- Peripheral B-cell receptor immunoglobulin heavy chain repertoire as a potential biomarker for frequently relapsing nephrotic syndrome in children. Renal failure · 27 Aug 2026 PMID 42655963
- Glucocorticoid in giant cell arteritis: real-world treatment patterns over time and associated burden in a nationwide hospital-based study within the French health insurance database. RMD open · 7 Jul 2026 PMID 42414038
- Glucocorticoid monotherapy versus combination with methotrexate or tocilizumab in giant cell arteritis: efficacy and safety at 78 weeks in a retrospective cohort study. Medicina clinica · 28 Jun 2026 PMID 42365805
- A cell-intrinsic glucocorticoid biosynthesis and sensing circuit maintains a homeostatic Th17 cell state. Immunity · 12 Jun 2026 PMID 42285103
Inflammatory Disease Treatment (4)
- No benefit of adding glucocorticoids to maintenance treatment in reducing the risk of major relapses in ANCA-associated vasculitis: real life data from a longitudinal cohort study. RMD open · 24 Jun 2026 PMID 42342286
- Glucocorticoid use among patients with rheumatoid arthritis during the first year of treatment-a cohort study. Rheumatology international · 12 Jun 2026 PMID 42283855
- Belumosudil in the Management of Heavily Pretreated Prolonged Chronic GVHD: A Retrospective Multicenter Real-World Study. Hematological oncology · 27 May 2026 PMID 42198791
- Glucocorticoids combined with anticoagulation modulate the central NLRP3/NETosis inflammatory process in patients with severe cerebral venous thrombosis: a human mechanistic exploratory study. Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 28 Apr 2026 PMID 42050165
Systemic Lupus Burden (2)
- Early SLE may follow a fast comorbidity/multimorbidity trajectory associated with flare burden and glucocorticoid exposure. RMD open · 23 Sept 2026 PMID 42778333
- Glucocorticoid exposure and social support deficits as longitudinal predictors of long-term neuropsychiatric damage in SLE: insights from the LUMINA cohort (LXXXIII). Lupus science & medicine · 22 Jul 2026 PMID 42486615
By study type
Observational studies and case reports (7)
- Peripheral B-cell receptor immunoglobulin heavy chain repertoire as a potential biomarker for frequently relapsing nephrotic syndrome in children. Renal failure · 27 Aug 2026 PMID 42655963
- Glucocorticoid exposure and social support deficits as longitudinal predictors of long-term neuropsychiatric damage in SLE: insights from the LUMINA cohort (LXXXIII). Lupus science & medicine · 22 Jul 2026 PMID 42486615
- Glucocorticoid in giant cell arteritis: real-world treatment patterns over time and associated burden in a nationwide hospital-based study within the French health insurance database. RMD open · 7 Jul 2026 PMID 42414038
- Glucocorticoid monotherapy versus combination with methotrexate or tocilizumab in giant cell arteritis: efficacy and safety at 78 weeks in a retrospective cohort study. Medicina clinica · 28 Jun 2026 PMID 42365805
- No benefit of adding glucocorticoids to maintenance treatment in reducing the risk of major relapses in ANCA-associated vasculitis: real life data from a longitudinal cohort study. RMD open · 24 Jun 2026 PMID 42342286
- Glucocorticoid use among patients with rheumatoid arthritis during the first year of treatment-a cohort study. Rheumatology international · 12 Jun 2026 PMID 42283855
- Belumosudil in the Management of Heavily Pretreated Prolonged Chronic GVHD: A Retrospective Multicenter Real-World Study. Hematological oncology · 27 May 2026 PMID 42198791
Human data, design not indexed (2)
- Early SLE may follow a fast comorbidity/multimorbidity trajectory associated with flare burden and glucocorticoid exposure. RMD open · 23 Sept 2026 PMID 42778333
- Glucocorticoids combined with anticoagulation modulate the central NLRP3/NETosis inflammatory process in patients with severe cerebral venous thrombosis: a human mechanistic exploratory study. Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 28 Apr 2026 PMID 42050165
Unclassified: not yet indexed with MeSH (1)
- A cell-intrinsic glucocorticoid biosynthesis and sensing circuit maintains a homeostatic Th17 cell state. Immunity · 12 Jun 2026 PMID 42285103
Written from 10 PubMed abstracts, each one listed by PMID above. Published: 2026-06-16. Last written: 2026-09-25 by GPT. Drafted by language models from published abstracts; not medical advice.